Last reviewed · How we verify
Kariva®
Kariva is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of ethinyl estradiol and desogestrel.
Kariva is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of ethinyl estradiol and desogestrel. Used for Contraception (prevention of pregnancy).
At a glance
| Generic name | Kariva® |
|---|---|
| Also known as | desogestrel/ethinyl estradiol |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Oral contraceptive (combined hormonal contraceptive) |
| Target | Progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | FDA-approved |
Mechanism of action
Kariva contains a progestin (desogestrel) and an estrogen (ethinyl estradiol) that work together to inhibit the luteinizing hormone (LH) surge required for ovulation. The progestin also thickens cervical mucus to impede sperm penetration and alters the endometrium to prevent implantation. This combination hormonal approach provides contraceptive efficacy through multiple mechanisms.
Approved indications
- Contraception (prevention of pregnancy)
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
Key clinical trials
- An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (PHASE1)
- Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083)
- A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021 (PHASE3)
- A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women (PHASE2)
- Growth Hormone in Poor Responders to IVF Trial (PHASE2, PHASE3)
- Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients (PHASE4)
- Hormonal Contraception and Vaginal Health (NA)
- NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kariva® CI brief — competitive landscape report
- Kariva® updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI